Accelrys' Q3 Sales and R&D Spend Flat as Loss Nearly Doubles; Announces Pfizer Alliance | GenomeWeb
NEW YORK (GenomeWeb News) — Accelrys today said third-quarter revenues increased 1 percent as R&D spending fell 5 percent and loss increased 90 percent.
Separately today, Accelrys said it will partner with Pfizer to develop cheminformatic software.
Total receipts for the three months ended Dec. 31, 2006, increased to $20.7 million from $20.4 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.